{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:49:01Z","timestamp":1790642941446,"version":"4.1.0"},"reference-count":232,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T00:00:00Z","timestamp":1587686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014549","name":"Stanford Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014549","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006521","name":"School of Medicine, Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00501","type":"journal-article","created":{"date-parts":[[2020,4,24]],"date-time":"2020-04-24T04:17:08Z","timestamp":1587701828000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":95,"title":["Bispecific Antibodies for Multiple Myeloma: A Review of Targets, Drugs, Clinical Trials, and Future Directions"],"prefix":"10.3389","volume":"11","author":[{"given":"Chiara","family":"Caraccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachi","family":"Krishna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darci J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Sch\u00fcrch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.clml.2018.06.015","article-title":"The multiple myeloma drug pipeline-2018: a review of small molecules and their therapeutic targets","volume":"18","author":"Abramson","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/cpt.550","article-title":"Daratumumab, elotuzumab, and the development of therapeutic monoclonal antibodies in multiple myeloma","volume":"101","author":"Laubach","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/asheducation-2010.1.489","article-title":"Ultra high-risk myeloma","volume":"2010","author":"Avet-Loiseau","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/leu.2015.309","article-title":"The clinical value of molecular subtyping multiple myeloma using gene expression profiling","volume":"30","author":"Weinhold","year":"2016","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11899-018-0472-8","article-title":"Bispecific antibodies for the treatment of acute myeloid leukemia","volume":"13","author":"Guy","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2515135518763280","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"6","author":"Dahl\u00e9n","year":"2018","journal-title":"Ther Adv Vaccines Immunother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1002\/ijc.10557","article-title":"Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody","volume":"100","author":"Dreier","year":"2002","journal-title":"Int J Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood-2018-99-118425","article-title":"Anti-BCMA BiTE\u00ae AMG 701 potently induces specific T cell lysis of human multiple myeloma (MM) cells and immunomodulation in the bone marrow microenvironment","volume":"132","author":"Cho","year":"2018","journal-title":"Blood"},{"key":"B15","unstructured":"CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma Watkins-YoonJ GuzmanW SomanchiA TheriaultJ NanjappaP NelsonA ASH"},{"key":"B16","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/annonc\/mdz269.038","article-title":"2020PA Novel bispecific BCMAxCD3 T cell-engaging antibody that treat multiple myeloma (MM) with minimal cytokine secretion","volume":"30","author":"Li","year":"2019","journal-title":"Ann Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/cas.12631","article-title":"Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma","volume":"106","author":"Zou","year":"2015","journal-title":"Cancer Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-18-2752","article-title":"Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific T-cell\u2013recruiting antibody optimized for cytotoxicity and cytokine release","volume":"25","author":"Zuch de Zafra","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1158\/2326-6066.CIR-17-0649","article-title":"A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1034\/j.1600-065X.2003.00009.x","article-title":"T cell anergy and costimulation","volume":"192","author":"Appleman","year":"2003","journal-title":"Immunol Rev"},{"key":"B21","unstructured":"32190777Hematology\/Oncology (Cancer) Approvals & Safety Notifications2019"},{"key":"B22","unstructured":"Drugs.com"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2002-11-3333","article-title":"CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma","volume":"102","author":"Robillard","year":"2003","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"B25","unstructured":"International Myeloma Foundation"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"JCO"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/leu.2011.204","article-title":"A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial","volume":"26","author":"Boyd","year":"2012","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013","volume":"88","author":"Mikhael","year":"2013","journal-title":"Mayo Clinic Proceed"},{"key":"B30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"B31","unstructured":"mSMART"},{"key":"B32","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the international myeloma working group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrc.2017.63","article-title":"Evolutionary biology of high-risk multiple myeloma","volume":"17","author":"Pawlyn","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1182\/blood-2018-04-842880","article-title":"The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma","volume":"132","author":"Rasche","year":"2018","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B Cell Maturation Antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","article-title":"From MGUS to multiple myeloma, a paradigm for clonal evolution of premalignant cells","volume":"78","author":"van Nieuwenhuijzen","year":"2018","journal-title":"Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1182\/blood.V88.6.2219.bloodjournal8862219","article-title":"Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein","volume":"88","author":"Urashima","year":"1996","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1158\/1078-0432.CCR-04-0632","article-title":"Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment","volume":"10","author":"Hayashi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e47077","DOI":"10.1371\/journal.pone.0047077","article-title":"Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma","volume":"7","author":"Muthu Raja","year":"2012","journal-title":"PLoS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1182\/blood-2016-05-636357","article-title":"The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies","volume":"128","author":"Hoyos","year":"2016","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/314628a0","article-title":"Hybrid antibodies can target sites for attack by T cells","volume":"314","author":"Staerz","year":"1985","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/316354a0","article-title":"Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody","volume":"316","author":"Perez","year":"1985","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","first-page":"539","DOI":"10.4161\/mabs.1.6.10015","article-title":"Bispecific antibodies for cancer therapy: the light at the end of the tunnel?","volume":"1","author":"Chames","year":"2009","journal-title":"MAbs"},{"key":"B48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-06-741058","article-title":"Redirecting T cells to hematological malignancies with bispecific antibodies","volume":"131","author":"Velasquez","year":"2018","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.4161\/mabs.2.2.11221","article-title":"Catumaxomab","volume":"2","author":"Linke","year":"2010","journal-title":"MAbs"},{"key":"B50","unstructured":"The Antibody Society"},{"key":"B51","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2450\/2019.0026-19","article-title":"Emicizumab for the treatment of haemophilia A: a narrative review","volume":"17","author":"Franchini","year":"2019","journal-title":"Blood Transfus"},{"key":"B52","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B53","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today"},{"key":"B54","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"key":"B55","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fimmu.2017.00038","article-title":"Fc engineering for developing therapeutic bispecific antibodies and novel scaffolds","volume":"8","author":"Liu","year":"2017","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"5879","DOI":"10.1073\/pnas.85.16.5879","article-title":"Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli","volume":"85","author":"Huston","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"B57","doi-asserted-by":"publisher","first-page":"980250","DOI":"10.1155\/2012\/980250","article-title":"scFv antibody: principles and clinical application","volume":"2012","author":"Ahmad","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4161\/mabs.3.1.14057","article-title":"A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting","volume":"3","author":"Schubert","year":"2011","journal-title":"MAbs"},{"key":"B59","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","article-title":"Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell\u2013engaging CD19\/CD3-bispecific BiTE antibody blinatumomab","volume":"119","author":"Klinger","year":"2012","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-015-0188-3","article-title":"AFM13: a first-in-class tetravalent bispecific anti-CD30\/CD16A antibody for NK cell-mediated immunotherapy","volume":"8","author":"Wu","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3390\/cancers11010055","article-title":"Exploiting NK cell surveillance pathways for cancer therapy","volume":"11","author":"Barrow","year":"2019","journal-title":"Cancers"},{"key":"B62","doi-asserted-by":"publisher","first-page":"8045","DOI":"10.1200\/JCO.2017.35.15_suppl.8045","article-title":"AFM26 is a novel, highly potent BCMA\/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma","volume":"35","author":"Gantke","year":"2017","journal-title":"JCO"},{"key":"B63","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00428-019-02725-3","article-title":"A review on tumor heterogeneity and evolution in multiple myeloma: pathological, radiological, molecular genetics, and clinical integration","volume":"476","author":"Sch\u00fcrch","year":"2019","journal-title":"Virchows Arch."},{"key":"B64","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1038\/bcj.2016.64","article-title":"Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma","volume":"6","author":"Jethava","year":"2016","journal-title":"Blood Cancer J"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1158\/1078-0432.CCR-15-2620","article-title":"Adverse metaphase cytogenetics can be overcome by adding bortezomib and thalidomide to fractionated melphalan transplants","volume":"23","author":"Jethava","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1182\/blood-2018-99-112899","article-title":"Double vs single autologous stem cell transplantation for newly diagnosed multiple myeloma: long-term follow-up (10-years) analysis of randomized phase 3 studies","volume":"132","author":"Cavo","year":"2018","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to train your T cells: overcoming immune dysfunction in multiple myeloma","volume":"26","author":"Cohen","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"13293","DOI":"10.1038\/s41598-019-49834-2","article-title":"Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy","volume":"9","author":"Maruta","year":"2019","journal-title":"Sci Rep"},{"key":"B70","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2147\/DDDT.S151282","article-title":"Bispecific antibodies: design, therapy, perspectives","volume":"12","author":"Sedykh","year":"2018","journal-title":"Drug Des Dev Ther"},{"key":"B71","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br J Pharmacol"},{"key":"B72","unstructured":"2009"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1182\/blood-2019-121805","article-title":"Safety, clinical activity, pharmacokinetics, and pharmacodynamics from a phase i study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"134","author":"Noopur","year":"","journal-title":"Blood."},{"key":"B74","unstructured":"AMG 420 Continues to Show Efficacy in Relapsed\/Refractory MyelomaASH Clinical News.2019"},{"key":"B75","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2217\/imt-2019-0074","article-title":"Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies","volume":"11","author":"Khadka","year":"2019","journal-title":"Immunotherapy"},{"key":"B76","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/s41409-019-0596-z","article-title":"The use of bispecific antibodies to optimize the outcome of patients with acute leukemia, lymphoma and multiple myeloma after SCT","volume":"54","author":"Einsele","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B78","unstructured":"Early-phase trial suggests bispecific antibody CC-93269 has activity in relapsed\/refractory multiple myeloma AhleS ASH Clin News.2020"},{"key":"B79","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/19420862.2019.1616506","article-title":"Redirected optimized cell killing (ROCK\u00ae): a highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity","volume":"11","author":"Ellwanger","year":"2019","journal-title":"MAbs"},{"key":"B80","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1182\/blood-2014-12-614636","article-title":"A phase 1 study of the bispecific anti-CD30\/CD16A antibody construct AFM13 in patients with relapsed or refractory hodgkin lymphoma","volume":"125","author":"Rothe","year":"2015","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fonc.2018.00285","article-title":"Rationale for combining bispecific T cell activating antibodies with checkpoint blockade for cancer therapy","volume":"8","author":"Kobold","year":"2018","journal-title":"Front Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/cpt.1396","article-title":"Bispecific antibodies in the treatment of hematologic malignancies","volume":"106","author":"Duell","year":"2019","journal-title":"Clin Pharmacol Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1038\/s41467-019-13196-0","article-title":"On-target restoration of a split T cell-engaging antibody for precision immunotherapy","volume":"10","author":"Banaszek","year":"2019","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody\u2013drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B85","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"B86","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3109\/08923973.2016.1153110","article-title":"Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization","volume":"38","author":"Chen","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B87","unstructured":"Preclinical characterization of an ANTI-CD38\/CD3 T CELL-redirecting bispecific antibody HeX ASH."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B89","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00262-012-1384-4","article-title":"Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors","volume":"62","author":"McCormack","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1093\/intimm\/10.11.1693","article-title":"The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily","volume":"10","author":"Madry","year":"1998","journal-title":"Int Immunol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0092-8674(01)00237-9","article-title":"The TNF and TNF receptor superfamilies: integrating mammalian biology","volume":"104","author":"Locksley","year":"2001","journal-title":"Cell"},{"key":"B93","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/intimm\/7.7.1093","article-title":"BCMAp: an integral membrane protein in the golgi apparatus of human mature B lymphocytes","volume":"7","author":"Gras","year":"1995","journal-title":"Int Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J Exp Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1172\/JCI18025","article-title":"BAFF selectively enhances the survival of plasmablasts generated from human memory B cells","volume":"112","author":"Avery","year":"2003","journal-title":"J Clin Invest"},{"key":"B96","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1182\/blood-2006-04-015958","article-title":"Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL","volume":"109","author":"Chiu","year":"2007","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"key":"B98","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/eji.201040591","article-title":"Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses","volume":"41","author":"Bossen","year":"2011","journal-title":"Eur J Immunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1084\/jem.192.11.1677","article-title":"A soluble form of B cell maturation antigen, a receptor for the tumor necrosis factor family member april, inhibits tumor cell growth","volume":"192","author":"Rennert","year":"2000","journal-title":"J Exp Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","article-title":"BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth","volume":"189","author":"Schneider","year":"1999","journal-title":"J Exp Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.4049\/jimmunol.165.3.1322","article-title":"TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-\u03baB, Elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase","volume":"165","author":"Hatzoglou","year":"2000","journal-title":"J Immunol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"key":"B103","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1182\/blood.V128.22.5641.5641","article-title":"Gene expression of Gamma Secretase (GS) complex-related proteins, the enzyme that sheds B-Cell maturation antigen (BCMA), among patients with multiple myeloma (MM) and effects of the GS inhibitor LSN424354 on solubilized bcma in MM and chronic lymphocytic leukemia","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","article-title":"Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma","volume":"22","author":"Sanchez","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B106","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood.2019000050","article-title":"\u03b3-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma","volume":"134","author":"Pont","year":"2019","journal-title":"Blood."},{"key":"B108","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B109","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1600-065X.2010.00944.x","article-title":"B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor","volume":"237","author":"Mackay","year":"2010","journal-title":"Immunol Rev"},{"key":"B110","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1128\/MCB.21.12.4067-4074.2001","article-title":"B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses","volume":"21","author":"Xu","year":"2001","journal-title":"Mol Cell Biol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1182\/blood-2018-99-110427","article-title":"A phase I, open-label study to evaluate the safety, pharmacokinetic, pharmacodynamic, and clinical activity of PF-06863135, a B-Cell maturation antigen\/CD3 bispecific antibody, in patients with relapsed\/refractory advanced multiple myeloma","volume":"132","author":"Lesokhin","year":"2018","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","first-page":"8017","DOI":"10.1200\/JCO.2017.35.15_suppl.8017","article-title":"Development of a fully human T cell engaging bispecific antibody for the treatment of multiple myeloma","volume":"35","author":"Buelow","year":"","journal-title":"J Clin Oncol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3324\/haematol.2013.097907","article-title":"Understanding the multiple biological aspects leading to myeloma","volume":"99","author":"Boyle","year":"2014","journal-title":"Haematologica"},{"key":"B114","unstructured":"Potential Myeloma Treatment, TNB-383B, Makes Progress in New DealMyeloma Research News.2019"},{"key":"B115","article-title":"TNB383B.001: a multicenter, phase 1, open-label, dose-escalation and expansion study of TNB-383B, a bispecific antibody targeting BCMA in subjects with relapsed or refractory multiple myeloma","author":"Buelow","year":"2019","journal-title":"American Society of Hematology 61st Annual Meeting and Exposition."},{"key":"B116","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1182\/blood-2019-126818","article-title":"Safety and preliminary clinical activity of REGN5458, an anti-Bcma x Anti-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"134","author":"Cooper","year":"2019","journal-title":"Blood"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1182\/blood-2018-99-112500","article-title":"REGN5458, a bispecific BCMAxCD3 T cell engaging antibody, demonstrates robust in vitro and in vivo anti-tumor efficacy in multiple myeloma models, comparable to that of BCMA CAR T cells","volume":"132","author":"Dilillo","year":"2018","journal-title":"Blood"},{"key":"B118","unstructured":"First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma"},{"key":"B119","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ymeth.2018.11.008","article-title":"Engineering therapeutic bispecific antibodies using CrossMab technology","volume":"154","author":"Klein","year":"2019","journal-title":"Methods"},{"key":"B120","unstructured":"First clinical study of the B-cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial CostaL ASH"},{"key":"B121","unstructured":"National Cancer Institute2011"},{"key":"B122","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1073\/pnas.1220145110","article-title":"Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B123","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1182\/blood.V128.22.5668.5668","article-title":"Exploratory pharmacokinetic\/pharmacodynamic and tolerability study of BCMAxCD3 in cynomolgus monkeys","volume":"128","author":"Girgis","year":"2016","journal-title":"Blood"},{"key":"B124","doi-asserted-by":"publisher","first-page":"TPS8067","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS8067","article-title":"Phase 1 dose-escalation study of BI 836909, an anti-BCMA bi-specific T-cell engager, in relapsed and\/or refractory multiple myeloma (RRMM)","volume":"34","author":"Topp","year":"2016","journal-title":"JCO"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/leu.2016.388","article-title":"A novel BCMA\/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo","volume":"31","author":"Hipp","year":"2017","journal-title":"Leukemia"},{"key":"B126","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1182\/blood.V126.23.2999.2999","article-title":"BI 836909, a novel bispecific T cell engager for the treatment of multiple myeloma induces highly specific and efficacious lysis of multiple myeloma cells in vitro and shows anti-tumor activity in vivo","volume":"126","author":"Hipp","year":"2015","journal-title":"Blood"},{"key":"B127","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti\u2013B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol."},{"key":"B128","unstructured":"BispecificT-cell Engager AMG 420 Active, Safe, in Heavily Pretreated Multiple Myeloma,. 2019"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1182\/blood-2018-99-109769","article-title":"Treatment with AMG 420, an anti-B-cell maturation antigen (BCMA) bispecific T-cell engager (BiTE\u00ae) antibody construct, induces minimal residual disease (MRD) negative complete responses in relapsed and\/or refractory (R\/R) multiple myeloma (MM) patients: results of a first-in-human (FIH) phase I dose escalation study","volume":"132","author":"Topp","year":"2018","journal-title":"Blood"},{"key":"B130","unstructured":""},{"key":"B131","unstructured":""},{"key":"B132","article-title":"AFM26 - A novel CD16A-directed bispecific antibody targeting BCMA for multiple myeloma","author":"Gantke","year":"2017","journal-title":"American Association for Cancer Research Annual Meeting"},{"key":"B133","unstructured":"CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma Watkins-YoonJ ASH."},{"key":"B134","doi-asserted-by":"crossref","first-page":"12304","DOI":"10.1016\/S0021-9258(17)32716-3","article-title":"Core protein structure and sequence determine the site and presence of heparan sulfate and chondroitin sulfate on syndecan-1","volume":"269","author":"Kokenyesi","year":"1994","journal-title":"J Biol Chem"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2014.12.003","article-title":"Advances in the molecular functions of syndecan-1 (SDC1\/CD138) in the pathogenesis of malignancies","volume":"94","author":"Gharbaran","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1083\/jcb.108.4.1547","article-title":"Molecular cloning of syndecan, an integral membrane proteoglycan","volume":"108","author":"Saunders","year":"1989","journal-title":"J Cell Biol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1309\/617DWB5GNFWXHW4L","article-title":"CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms","volume":"121","author":"O'Connell","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1182\/blood-2002-06-1737","article-title":"Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development","volume":"101","author":"Zhan","year":"2003","journal-title":"Blood"},{"key":"B139","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10585-007-9125-3","article-title":"Syndecan-1: a dynamic regulator of the myeloma microenvironment","volume":"25","author":"Sanderson","year":"2008","journal-title":"Clin Exp Metastasis"},{"key":"B140","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1046\/j.1365-2141.1998.00623.x","article-title":"The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells","volume":"100","author":"Jourdan","year":"1998","journal-title":"Br J Haematol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1158\/0008-5472.CAN-16-0232","article-title":"Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: prevention by SynstatinIGF1R inhibits tumor growth","volume":"76","author":"Beauvais","year":"2016","journal-title":"Cancer Res"},{"key":"B142","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0609.2009.01262.x","article-title":"APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop","volume":"83","author":"Moreaux","year":"2009","journal-title":"Eur J Haematol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1182\/blood.V96.9.3139.h8003139_3139_3146","article-title":"High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity","volume":"96","author":"Seidel","year":"2000","journal-title":"Blood"},{"key":"B144","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1046\/j.1365-2141.1997.3893203.x","article-title":"Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma","volume":"99","author":"Dhodapkar","year":"1997","journal-title":"Br J Haematol"},{"key":"B145","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/j.1365-2141.2005.05647.x","article-title":"Soluble syndecan-1 level at diagnosis is an independent prognostic factor in multiple myeloma and the extent of fall from diagnosis to plateau predicts for overall survival","volume":"130","author":"Lovell","year":"2005","journal-title":"Br J Haematol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1084\/jem.20011097","article-title":"Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells","volume":"195","author":"Dhodapkar","year":"2002","journal-title":"J Exp Med"},{"key":"B147","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1111\/j.1751-553X.2010.01222.x","article-title":"Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma","volume":"32","author":"Reid","year":"2010","journal-title":"Int J Lab Hematol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood.V118.21.305.305","article-title":"BT062, an antibody-drug conjugate directed against CD138, shows clinical activity in patients with relapsed or relapsed\/refractory multiple myeloma","volume":"118","author":"Jagannath","year":"2011","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0145-2126(00)00093-X","article-title":"Human CD38: a (r)evolutionary story of enzymes and receptors","volume":"25","author":"Deaglio","year":"2001","journal-title":"Leukemia Res"},{"key":"B150","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/jcb.21887","article-title":"CD38 is constitutively expressed in the nucleus of human hematopoietic cells","volume":"105","author":"Orciani","year":"2008","journal-title":"J Cell Biochem"},{"key":"B151","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2119\/2006-00086.Lee","article-title":"Structure and enzymatic functions of human CD38","volume":"12","author":"Lee","year":"2006","journal-title":"Mol Med"},{"key":"B152","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4049\/jimmunol.160.1.395","article-title":"Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member","volume":"160","author":"Deaglio","year":"1998","journal-title":"J Immunol"},{"key":"B153","doi-asserted-by":"crossref","first-page":"952","DOI":"10.4049\/jimmunol.153.3.952","article-title":"Interaction between endothelium and CD4+CD45RA+ lymphocytes","volume":"153","author":"Dianzani","year":"1994","journal-title":"J Immunol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance","volume":"9","author":"van de Donk","year":"2018","journal-title":"Front Immunol"},{"key":"B155","doi-asserted-by":"publisher","first-page":"4729","DOI":"10.1182\/blood.V124.21.4729.4729","article-title":"SAR 650984, a therapeutic anti-CD38 monoclonal antibody, blocks CD38-CD31 interaction in multiple myeloma","volume":"124","author":"An","year":"2014","journal-title":"Blood"},{"key":"B156","doi-asserted-by":"publisher","first-page":"09","DOI":"10.1186\/1753-6561-7-S6-O9","article-title":"BEAT\u00ae the bispecific challenge: a novel and efficient platform for the expression of bispecific IgGs","volume":"7","author":"Moretti","year":"2013","journal-title":"BMC Proc"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3132","article-title":"Phase 1, multicenter, open-label study of single-agent bispecific antibody T-cell engager GBR 1342 in relapsed\/refractory multiple myeloma","volume":"36","author":"Richter","year":"2018","journal-title":"J Clin Oncol."},{"key":"B158","unstructured":"Glenmark Pharmaceuticals Announces Decision to Launch Phase 1 Trial in Solid Tumors for its CD38xCD3 Bispecific Antibody GBR 1342 Based on Human Translational Data"},{"key":"B159","unstructured":"Myeloma Research News2019"},{"key":"B160","unstructured":"Sorrento Therapeutics : Form of Prospectus Disclosing Information, Facts, Events Covered in Both Forms 424B2, 424B3 | MarketScreener"},{"key":"B161","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrrheum.2009.184","article-title":"CD19: a promising B cell target for rheumatoid arthritis","volume":"5","author":"Tedder","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp Hematol Oncol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1006\/smim.1998.9999","article-title":"CD19 regulates B lymphocyte responses to transmembrane signals","volume":"10","author":"Fujimoto","year":"1998","journal-title":"Semin Immunol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.4049\/jimmunol.1201000","article-title":"A c-Myc and surface CD19 signaling amplification loop promotes B cell lymphoma development and progression in mice","volume":"189","author":"Poe","year":"2012","journal-title":"J Immunol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1074-7613(00)80418-5","article-title":"The CD19\u2013CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity","volume":"6","author":"Tedder","year":"1997","journal-title":"Immunity"},{"key":"B166","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1385\/IR:31:2:119","article-title":"CD19 function in central and peripheral B-cell development","volume":"31","author":"Del Nagro","year":"2005","journal-title":"Immunol Res"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1056\/NEJMoa051568","article-title":"An antibody-deficiency syndrome due to mutations in the CD19 gene","volume":"354","author":"van Zelm","year":"2006","journal-title":"N Engl J Med"},{"key":"B168","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/0-387-24180-9_16","article-title":"Role of the CD19 and CD21\/35 receptor complex in innate immunity, host defense and autoimmunity","volume":"560","author":"Haas","year":"2005","journal-title":"Adv Exp Med Biol"},{"key":"B169","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/eji.200939848","article-title":"Differential phosphorylation of functional tyrosines in CD19 modulates B-lymphocyte activation","volume":"40","author":"Ishiura","year":"2010","journal-title":"Eur J Immunol"},{"key":"B170","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1080\/10428190290012146","article-title":"CD19 expression and growth inhibition of tumours in human multiple myeloma","volume":"43","author":"Ishikawa","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"B171","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa1504542","article-title":"Chimeric antigen receptor T cells against CD19 for multiple myeloma","volume":"373","author":"Garfall","year":"2015","journal-title":"N Engl J Med"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.26420\/annhematoloncol.2017.1174","article-title":"Blinatumomab induced response of multiply refractory multiple myeloma in the context of secondary pre-B cell acute lymphoblastic leukemia","volume":"4","author":"Pratz","year":"2017","journal-title":"Ann Hematol Oncol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1038\/s41467-019-10948-w","article-title":"Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T","volume":"10","author":"Nerreter","year":"2019","journal-title":"Nat Commun"},{"key":"B174","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/2040620716640422","article-title":"The role of blinatumomab in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"7","author":"Benjamin","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"B175","unstructured":"FDA2018"},{"key":"B176","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med."},{"key":"B177","unstructured":"National Cancer Institute2017"},{"key":"B178","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0161-5890(02)00094-9","article-title":"CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function","volume":"39","author":"Kumaresan","year":"2002","journal-title":"Mol Immunol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.4049\/jimmunol.179.7.4672","article-title":"CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes","volume":"179","author":"Lee","year":"2007","journal-title":"J Immunol"},{"key":"B180","doi-asserted-by":"publisher","first-page":"a002469","DOI":"10.1101\/cshperspect.a002469","article-title":"SLAM-family receptors: immune regulators with or without SAP-family adaptors","volume":"2","author":"Veillette","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.imlet.2010.09.021","article-title":"Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: from pro-B to plasma cells","volume":"134","author":"De Salort","year":"2011","journal-title":"Immunol Lett"},{"key":"B182","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B183","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"key":"B184","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/blood.V108.11.660.660","article-title":"CS1 is expressed on myeloma cells from early stage, late stage, and drug-treated multiple myeloma patients, and is selectively targeted by the HuLuc63 antibody","volume":"108","author":"Szmania","year":"2006","journal-title":"Blood"},{"key":"B185","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.critrevonc.2013.04.003","article-title":"CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma","volume":"88","author":"Veillette","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"B186","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.molmed.2008.02.004","article-title":"The NKG2D receptor: sensing stressed cells","volume":"14","author":"L\u00f3pez-Larrea","year":"2008","journal-title":"Trends Mol Med"},{"key":"B187","doi-asserted-by":"publisher","first-page":"5739","DOI":"10.4049\/jimmunol.1202860","article-title":"Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from that of Fc-receptors","volume":"190","author":"Franco","year":"2013","journal-title":"J Immunol"},{"key":"B188","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"B189","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1182\/blood.V91.5.1732.1732_1732_1741","article-title":"Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin","volume":"91","author":"Sawyer","year":"1998","journal-title":"Blood"},{"key":"B190","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1074-7613(01)00109-1","article-title":"IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy","volume":"14","author":"Hatzivassiliou","year":"2001","journal-title":"Immunity"},{"key":"B191","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s00262-010-0844-y","article-title":"Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen","volume":"59","author":"Bluemel","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B192","doi-asserted-by":"publisher","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell\u2013dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"key":"B193","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/19420862.2018.1551676","article-title":"Single cell-produced and in vitro-assembled anti-FcRH5\/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties","volume":"11","author":"Ovacik","year":"2019","journal-title":"MAbs"},{"key":"B194","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","article-title":"Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma","volume":"42","author":"Atamaniuk","year":"2012","journal-title":"Eur J Clin Invest"},{"key":"B195","unstructured":""},{"key":"B196","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0167-4781(01)00197-X","article-title":"Cloning and characterization of a human orphan family C G-protein coupled receptor GPRC5D","volume":"1518","author":"Br\u00e4uner-Osborne","year":"2001","journal-title":"Biochim Biophys Acta"},{"key":"B197","unstructured":""},{"key":"B198","unstructured":""},{"key":"B199","unstructured":""},{"key":"B200","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/blood.2019003342","article-title":"A T cell redirecting bispecific g-protein coupled receptor class 5 member DxCD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood."},{"key":"B201","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood-2007-05-088674","article-title":"The multiple myeloma\u2013associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity","volume":"111","author":"Lauring","year":"2008","journal-title":"Blood"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-230X(06)95001-5","article-title":"NY-ESO-1: review of an immunogenic tumor antigen","volume":"95","author":"Gnjatic","year":"2006","journal-title":"Adv Cancer Res."},{"key":"B203","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"B204","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1038\/sj.emboj.7601235","article-title":"Yeast homolog of a cancer-testis antigen defines a new transcription complex","volume":"25","author":"Kisseleva-Romanova","year":"2006","journal-title":"EMBO J"},{"key":"B205","first-page":"12","article-title":"Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6)","volume":"6","author":"Cho","year":"2006","journal-title":"Cancer Immun"},{"key":"B206","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/jnr.10160","article-title":"The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease","volume":"67","author":"Barker","year":"2002","journal-title":"J Neurosci Res"},{"key":"B207","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1158\/0008-5472.CAN-04-1882","article-title":"Cancer\/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression","volume":"65","author":"Cronwright","year":"2005","journal-title":"Cancer Res"},{"key":"B208","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1182\/blood-2004-09-3707","article-title":"NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses","volume":"105","author":"van Rhee","year":"2005","journal-title":"Blood"},{"key":"B209","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1084\/jem.187.2.265","article-title":"Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes","volume":"187","author":"J\u00e4ger","year":"1998","journal-title":"J Exp Med"},{"key":"B210","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00262-014-1588-x","article-title":"Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation","volume":"63","author":"Luetkens","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B211","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1046\/j.1365-2141.1997.2173032.x","article-title":"Assessment of intracellular TAP-1 and TAP-2 in conjunction with surface MHC class I in plasma cells from patients with multiple myeloma","volume":"98","author":"Crucian","year":"1997","journal-title":"Br J Haematol"},{"key":"B212","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1084\/jem.180.4.1415","article-title":"Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing","volume":"180","author":"Gabathuler","year":"1994","journal-title":"J Exp Med"},{"key":"B213","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/BF00047751","article-title":"IFN-induced modulation of histocompatibility antigens on human cells","volume":"7","author":"Hokland","year":"1988","journal-title":"Cancer Metastasis Rev"},{"key":"B214","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.4049\/jimmunol.149.7.2372","article-title":"IFN increases class I MHC antigen expression on adenovirus-infected human cells without inducing resistance to natural killer cell killing","volume":"149","author":"Routes","year":"1992","journal-title":"J Immunol"},{"key":"B215","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/nm.2764","article-title":"Monoclonal TCR-redirected tumor cell killing","volume":"18","author":"Liddy","year":"2012","journal-title":"Nat Med"},{"key":"B216","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00262-007-0412-2","article-title":"Soluble factors released by activated cytotoxic T lymphocytes interfere with death receptor pathways in neuroblastoma","volume":"57","author":"De Geer","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B217","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","article-title":"Complete hematologic and molecular response in adult patients with relapsed\/refractory philadelphia chromosome\u2013positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study","volume":"35","author":"Martinelli","year":"2017","journal-title":"JCO"},{"key":"B218","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1517\/14740338.2011.562188","article-title":"The potential risk of infections during (prolonged) rituximab therapy in rheumatoid arthritis","volume":"10","author":"Brinkman","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"B219","unstructured":""},{"key":"B220","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2019","journal-title":"Nat Cancer"},{"key":"B221","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.immuni.2016.04.020","article-title":"CD28 costimulation: from mechanism to therapy","volume":"44","author":"Esensten","year":"2016","journal-title":"Immunity"},{"key":"B222","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"B223","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1038\/leu.2016.84","article-title":"Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade","volume":"30","author":"Suen","year":"2016","journal-title":"Leukemia"},{"key":"B224","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-015-0213-6","article-title":"Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19\/CD3-bispecific T cell engager antibody blinatumomab","volume":"8","author":"K\u00f6hnke","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B225","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","article-title":"Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma","volume":"21","author":"G\u00f6rg\u00fcn","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B226","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/leu.2015.214","article-title":"Blockade of the PD-1\/PD-L1 axis augments lysis of AML cells by the CD33\/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism","volume":"30","author":"Krupka","year":"2016","journal-title":"Leukemia"},{"key":"B227","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1038\/bcj.2015.68","article-title":"T-cell ligands modulate the cytolytic activity of the CD33\/CD3 BiTE antibody construct, AMG 330","volume":"5","author":"Laszlo","year":"2015","journal-title":"Blood Cancer J"},{"key":"B228","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"B229","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B230","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.bbmt.2015.12.030","article-title":"Targeting CD138\u2013\/CD20+ clonogenic myeloma precursor cells decreases these cells and induces transferable antimyeloma immunity","volume":"22","author":"Lum","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"B231","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1084\/jem.20062387","article-title":"Frequent and specific immunity to the embryonal stem cell\u2013associated antigen SOX2 in patients with monoclonal gammopathy","volume":"204","author":"Spisek","year":"2007","journal-title":"J Exp Med"},{"key":"B232","doi-asserted-by":"publisher","first-page":"7600","DOI":"10.1158\/0008-5472.CAN-10-2126","article-title":"A bispecific antibody-IFN\u03b12b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells","volume":"70","author":"Rossi","year":"2010","journal-title":"Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00501\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T08:18:45Z","timestamp":1696061925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00501\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,24]]},"references-count":232,"alternative-id":["10.3389\/fimmu.2020.00501"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00501","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,24]]},"article-number":"501"}}